.Pharmacolibrary.Drugs.ATC.J.J05AX18

Information

Letermovir is an antiviral medication approved for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). It works as a CMV DNA terminase complex inhibitor and is currently approved and in clinical use.

Pharmacokinetics

Pharmacokinetic model parameters for healthy adult subjects, mainly following oral administration, as reported in published population pharmacokinetic studies.

References

1. Prohn, M, et al., & Cho, CR (2021). Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients. CPT: pharmacometrics & systems pharmacology 10(3) 255–267. DOI:10.1002/psp4.12593 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33440077

2. Suetsugu, K, et al., & Ieiri, I (2024). Clinical Pharmacokinetics and Pharmacodynamics of Letermovir in Allogenic Hematopoietic Cell Transplantation. Clinical pharmacokinetics 63(7) 945–964. DOI:10.1007/s40262-024-01392-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39012618

3. Asari, K, et al., & Iwamoto, M (2022). Pharmacokinetics, Safety, and Tolerability of Letermovir Following Single- and Multiple-Dose Administration in Healthy Japanese Subjects. Clinical pharmacology in drug development 11(8) 938–948. DOI:10.1002/cpdd.1081 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35238179

Revisions

• 06/2025 initial generated model